{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,3]],"date-time":"2026-09-03T23:16:46Z","timestamp":1788477406799,"version":"build-2803163510"},"reference-count":89,"publisher":"Frontiers Media SA","license":[{"start":{"date-parts":[[2025,3,28]],"date-time":"2025-03-28T00:00:00Z","timestamp":1743120000000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"content-domain":{"domain":["frontiersin.org"],"crossmark-restriction":true},"short-container-title":["Front. Immunol."],"abstract":"<jats:sec><jats:title>Background and purpose<\/jats:title><jats:p>Promoting adaptive immunity with ICIs has drastically improved melanoma prognosis, but not for all patients. Some cases relapse in the first few months, while others keep durable benefit, even after immunotherapy discontinuation. To identify cellular\/molecular signatures in peripheral blood that could differentiate advanced from metastatic melanoma and predict dynamics for primary\/secondary immune escape, we examined 100 consecutive patients with stage III\/IV melanoma scheduled to start ICIs.<\/jats:p><\/jats:sec><jats:sec><jats:title>Materials and methods<\/jats:title><jats:p>At melanoma diagnosis, a multiparameter flow cytometric analysis and purification scheme using standard conjugated antibodies were performed for all individuals prior to ICI initiation. In each stage(III\/IV) according to their RFS\/PFS, we retrospectively selected the cases with the clearest clinical outcomes and focused our analysis on the extreme responders(n=7) and non-responders(n=7) to characterize the transcriptomes of circulating CD4<jats:sup>+<\/jats:sup>T-cells by bulk RNA-seq, Differential Expression Analysis(DEA)and Gene Ontology(GO)enrichment analysis. Based on our selected patient cohort, we examined for differentially expressed genes(DEGs)and key-pathways that appear preferentially activated in stage III vs. IV melanoma, and in long vs. short immunotherapy responders.<\/jats:p><\/jats:sec><jats:sec><jats:title>Results<\/jats:title><jats:p>Although circulating immune-cells did not numerically differ in both sets of analysis(staging and ICI responsiveness), DEA and GO data showed that patients could be clustered separately, identifying 189vs.92 DEGs in stage IV\/III and 101vs.47 DEGs in early progressors\/long responders. These DEGs were functionally implicated in distinct pathways. For metastatic cases: inflammatory response(logp-value=-9.2:ADGRE5\/2,CYBA,GRN,HMOX1,IRF5,ITGAM), adaptive immunity(logp-value=-7.7:CD1C,CD74,CYBB,NCF2,CTSA,S100A8\/9,BCL3,FCER1G), T-cell activation(logp-value=-6.3:BCL3,CD1C,CD74,FCER1G,FGL2)and lipid metabolism\/catabolism(logp-value=-2.5\/-2.6:ARF3,GPX1,MVD,OCRL,PCCB,CTSA,PNPLA2,NAGLU,GBA2,ABHD4); while in early-progressors to ICIs: immune effector processing(logp-value=-13.7:BCL6,FGR,HLA-DQA1\/DQB1,HLA-DRA,HLA-DRB1\/DRB5,NKG7,SLC11A1,TYROBP,SPON2,HAVCR2),PD-1(logp-value=-10.2:HLA-DQA1\/DQB1,HLA-DRA,HLA-DRB1\/DRB5)and IFN signaling(logp-value=-8.5: HLA-DQA1\/DQB1,HLA-DRA,HLA-DRB1\/DRB5,NCAM1,IFITM3),positive regulation of T-cell activation(logp-value=-7.7:BCL6,HLA-DQA1\/DQB1,HLA-DRA,HLA-DRB1\/DRB5,SASH3,HAVCR2)and CD28 co-stimulation(logp-value=-10.3:HLA-DQA1\/DQB1,HLA-DRA,HLA-DRB1\/DRB5), supporting an immune-mediated behavior.<\/jats:p><\/jats:sec><jats:sec><jats:title>Conclusions<\/jats:title><jats:p>Specific pathways and marker genes in the peripheral CD4<jats:sup>+<\/jats:sup>T-cells may predetermine melanoma staging and immunotherapy resistance.<\/jats:p><\/jats:sec>","DOI":"10.3389\/fimmu.2025.1529707","type":"journal-article","created":{"date-parts":[[2025,3,28]],"date-time":"2025-03-28T09:38:45Z","timestamp":1743154725000},"update-policy":"https:\/\/doi.org\/10.3389\/crossmark-policy","source":"Crossref","is-referenced-by-count":1,"title":["Transcriptomic signatures in peripheral CD4+T-lymphocytes may reflect melanoma staging and immunotherapy responsiveness prior to ICI initiation"],"prefix":"10.3389","volume":"16","author":[{"given":"Eleni","family":"Palli","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Matthieu","family":"Lavigne","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Panagiotis","family":"Verginis","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Themis","family":"Alissafi","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Amalia","family":"Anastasopoulou","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Georgios","family":"Lyrarakis","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"John M.","family":"Kirkwood","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Helen","family":"Gogas","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Dimitrios C.","family":"Ziogas","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"1965","published-online":{"date-parts":[[2025,3,28]]},"reference":[{"key":"B1","doi-asserted-by":"publisher","DOI":"10.1016\/S1470-2045(20)30494-0","article-title":"Adjuvant nivolumab versus ipilimumab in resected stage iiib-C and stage iv melanoma (Checkmate 238): 4-year results from a multicentre, double-blind, randomised, controlled, phase 3 trial","volume":"21","author":"Ascierto","year":"2020","journal-title":"Lancet Oncol"},{"key":"B2","doi-asserted-by":"publisher","DOI":"10.1016\/S1470-2045(21)00065-6","article-title":"Adjuvant pembrolizumab versus placebo in resected stage iii melanoma (Eortc 1325-mg\/keynote-054): distant metastasis-free survival results from a double-blind, randomised, controlled, phase 3 trial","volume":"22","author":"Eggermont","year":"2021","journal-title":"Lancet Oncol"},{"key":"B3","doi-asserted-by":"publisher","DOI":"10.1016\/j.annonc.2024.08.2330","article-title":"Pembrolizumab versus ipilimumab for advanced melanoma: 10-year follow-up of the phase iii keynote-006 study","volume":"35","author":"Long","year":"2024","journal-title":"Ann Oncol"},{"key":"B4","doi-asserted-by":"publisher","first-page":"11","DOI":"10.1056\/NEJMoa2407417","article-title":"Final, 10-year outcomes with nivolumab plus ipilimumab in advanced melanoma","volume":"392","author":"Wolchok","year":"2025","journal-title":"N Engl J Med"},{"key":"B5","doi-asserted-by":"publisher","DOI":"10.1016\/j.ctrv.2022.102499","article-title":"Mechanisms of resistance to immune checkpoint inhibitors in melanoma: what we have to overcome","volume":"113","author":"Ziogas","year":"2023","journal-title":"Cancer Treat Rev"},{"key":"B6","doi-asserted-by":"publisher","DOI":"10.1002\/(SICI)1097-0142(19960401)77:7<1303::AID-CNCR12>3.0.CO;2-5","article-title":"Prognostic value of tumor infiltrating lymphocytes in the vertical growth phase of primary cutaneous melanoma","volume":"77","author":"Clemente","year":"1996","journal-title":"Cancer"},{"key":"B7","doi-asserted-by":"publisher","DOI":"10.1158\/1078-0432.CCR-13-2508","article-title":"Myeloid-derived suppressor cells predict survival of patients with advanced melanoma: comparison with regulatory T cells and ny-eso-1- or melan-a-specific T cells","volume":"20","author":"Weide","year":"2014","journal-title":"Clin Cancer Res"},{"key":"B8","doi-asserted-by":"publisher","DOI":"10.1158\/1078-0432.CCR-14-1015","article-title":"Circulating cd4+ T cells that produce il4 or il17 when stimulated by melan-a but not by ny-eso-1 have negative impacts on survival of patients with stage iv melanoma","volume":"20","author":"Zelba","year":"2014","journal-title":"Clin Cancer Res"},{"key":"B9","doi-asserted-by":"publisher","DOI":"10.1158\/1078-0432.CCR-14-1371","article-title":"Promising cell-based immunotherapy using gamma delta T cells: together is better","volume":"20","author":"Dechanet-Merville","year":"2014","journal-title":"Clin Cancer Res"},{"key":"B10","doi-asserted-by":"publisher","DOI":"10.1038\/onc.2008.267","article-title":"Nk cells and cancer immunosurveillance","volume":"27","author":"Waldhauer","year":"2008","journal-title":"Oncogene"},{"key":"B11","doi-asserted-by":"publisher","DOI":"10.1073\/pnas.1110814108","article-title":"Integrated ny-eso-1 antibody and cd8+ T-cell responses correlate with clinical benefit in advanced melanoma patients treated with ipilimumab","volume":"108","author":"Yuan","year":"2011","journal-title":"Proc Natl Acad Sci U.S.A"},{"key":"B12","doi-asserted-by":"publisher","first-page":"599","DOI":"10.1038\/nri.2016.80","article-title":"Regulatory circuits of T cell function in cancer","volume":"16","author":"Speiser","year":"2016","journal-title":"Nat Rev Immunol"},{"key":"B13","doi-asserted-by":"publisher","DOI":"10.1126\/sciadv.abe3348","article-title":"Tumor-specific cytolytic cd4 T cells mediate immunity against human cancer","volume":"7","author":"Cachot","year":"2021","journal-title":"Sci Adv"},{"key":"B14","doi-asserted-by":"publisher","first-page":"998","DOI":"10.1016\/j.cell.2018.10.038","article-title":"Defining T cell states associated with response to checkpoint immunotherapy in melanoma","volume":"175","author":"Sade-Feldman","year":"2018","journal-title":"Cell"},{"key":"B15","doi-asserted-by":"publisher","DOI":"10.1038\/s41591-019-0522-3","article-title":"Clonal replacement of tumor-specific T cells following pd-1 blockade","volume":"25","author":"Yost","year":"2019","journal-title":"Nat Med"},{"key":"B16","doi-asserted-by":"publisher","DOI":"10.1038\/s41586-020-2056-8","article-title":"Peripheral T cell expansion predicts tumour infiltration and clinical response","volume":"579","author":"Wu","year":"2020","journal-title":"Nature"},{"key":"B17","doi-asserted-by":"publisher","first-page":"1612","DOI":"10.1016\/j.cell.2020.05.017","article-title":"Intratumoral cd4(+) T cells mediate anti-tumor cytotoxicity in human bladder cancer","volume":"181","author":"Oh","year":"2020","journal-title":"Cell"},{"key":"B18","doi-asserted-by":"publisher","DOI":"10.1038\/s41586-022-04682-5","article-title":"Landscape of helper and regulatory antitumour cd4(+) T cells in melanoma","volume":"605","author":"Oliveira","year":"2022","journal-title":"Nature"},{"key":"B19","doi-asserted-by":"publisher","DOI":"10.1007\/s11605-017-3446-6","article-title":"Increased infiltration of natural killer and T cells in colorectal liver metastases improves patient overall survival","volume":"21","author":"Donadon","year":"2017","journal-title":"J Gastrointest Surg"},{"key":"B20","doi-asserted-by":"publisher","DOI":"10.1038\/s41577-018-0044-0","article-title":"Cd4(+) T cell help in cancer immunology and immunotherapy","volume":"18","author":"Borst","year":"2018","journal-title":"Nat Rev Immunol"},{"key":"B21","doi-asserted-by":"publisher","DOI":"10.1016\/j.it.2024.02.005","article-title":"Regulation and impact of tumor-specific cd4(+) T cells in cancer and immunotherapy","volume":"45","author":"Guo","year":"2024","journal-title":"Trends Immunol"},{"key":"B22","doi-asserted-by":"publisher","DOI":"10.1016\/j.trecan.2024.07.009","article-title":"Cd4(+) T cells in antitumor immunity","volume":"10","author":"Montauti","year":"2024","journal-title":"Trends\u00a0Cancer"},{"key":"B23","doi-asserted-by":"publisher","DOI":"10.1136\/jitc-2024-010170","article-title":"Depletion of conventional cd4(+) T cells is required for robust priming and dissemination of tumor antigen-specific cd8(+) T cells in the setting of anti-cd4 therapy","volume":"12","author":"Ramirez","year":"2024","journal-title":"J Immunother Cancer"},{"key":"B24","doi-asserted-by":"publisher","DOI":"10.1016\/j.immuni.2021.11.015","article-title":"Cytotoxic cd4(+) T cells in cancer: expanding the immune effector toolbox","volume":"54","author":"Oh","year":"2021","journal-title":"Immunity"},{"key":"B25","doi-asserted-by":"publisher","first-page":"5","DOI":"10.1038\/s41417-020-0183-x","article-title":"Revisiting the role of cd4(+) T cells in cancer immunotherapy-new insights into old paradigms","volume":"28","author":"Tay","year":"2021","journal-title":"Cancer Gene Ther"},{"key":"B26","doi-asserted-by":"publisher","DOI":"10.1158\/0008-5472.CAN-12-3381","article-title":"Higher frequencies of garp(+)Ctla-4(+)Foxp3(+) T regulatory cells and myeloid-derived suppressor cells in hepatocellular carcinoma patients are associated with impaired T-cell functionality","volume":"73","author":"Kalathil","year":"2013","journal-title":"Cancer Res"},{"key":"B27","doi-asserted-by":"publisher","DOI":"10.1097\/CMR.0000000000000633","article-title":"Absolute lymphocyte count as a prognostic biomarker for overall survival in patients with advanced melanoma treated with ipilimumab","volume":"30","author":"Postow","year":"2020","journal-title":"Melanoma Res"},{"key":"B28","doi-asserted-by":"publisher","DOI":"10.1158\/1078-0432.CCR-16-0249","article-title":"Increases in absolute lymphocytes and circulating cd4+ and cd8+ T cells are associated with positive clinical outcome of melanoma patients treated with ipilimumab","volume":"22","author":"Martens","year":"2016","journal-title":"Clin Cancer Res"},{"key":"B29","doi-asserted-by":"publisher","DOI":"10.1038\/bjc.2015.467","article-title":"Serum lactate dehydrogenase as an early marker for outcome in patients treated with anti-pd-1 therapy in metastatic melanoma","volume":"114","author":"Diem","year":"2016","journal-title":"Br J Cancer"},{"key":"B30","doi-asserted-by":"publisher","DOI":"10.1158\/1078-0432.CCR-16-0127","article-title":"Baseline biomarkers for outcome of melanoma patients treated with pembrolizumab","volume":"22","author":"Weide","year":"2016","journal-title":"Clin Cancer Res"},{"key":"B31","doi-asserted-by":"publisher","DOI":"10.4049\/jimmunol.1600875","article-title":"Establishing high dimensional immune signatures from peripheral blood via mass cytometry in a discovery cohort of stage iv melanoma patients","volume":"198","author":"Wistuba-Hamprecht","year":"2017","journal-title":"J Immunol"},{"key":"B32","doi-asserted-by":"publisher","DOI":"10.1038\/nm.4466","article-title":"High-dimensional single-cell analysis predicts response to anti-pd-1 immunotherapy","volume":"24","author":"Krieg","year":"2018","journal-title":"Nat Med"},{"key":"B33","unstructured":""},{"key":"B34","unstructured":""},{"key":"B35","doi-asserted-by":"publisher","DOI":"10.1038\/s41587-019-0201-4","article-title":"Graph-based genome alignment and genotyping with hisat2 and hisat-genotype","volume":"37","author":"Kim","year":"2019","journal-title":"Nat Biotechnol"},{"key":"B36","doi-asserted-by":"publisher","DOI":"10.1093\/bioinformatics\/btac166","article-title":"Analysing high-throughput sequencing data in python with htseq 2.0","volume":"38","author":"Putri","year":"2022","journal-title":"Bioinformatics"},{"key":"B37","unstructured":""},{"key":"B38","unstructured":""},{"key":"B39","unstructured":""},{"key":"B40","doi-asserted-by":"publisher","DOI":"10.1177\/1758835920929583","article-title":"Surrogate endpoints for overall survival in anti-programmed death-1 and anti-programmed death ligand 1 trials of advanced melanoma","volume":"12","author":"Nie","year":"2020","journal-title":"Ther Adv Med Oncol"},{"key":"B41","doi-asserted-by":"publisher","DOI":"10.3389\/fimmu.2021.707217","article-title":"Haplotype-specific expression analysis of mhc class ii genes in healthy individuals and rheumatoid arthritis patients","volume":"12","author":"Houtman","year":"2021","journal-title":"Front Immunol"},{"key":"B42","doi-asserted-by":"publisher","DOI":"10.1016\/j.patter.2021.100293","article-title":"Interpretable systems biomarkers predict response to immune-checkpoint inhibitors","volume":"2","author":"Lapuente-Santana","year":"2021","journal-title":"Patterns (N Y)"},{"key":"B43","doi-asserted-by":"publisher","DOI":"10.4049\/jimmunol.1103160","article-title":"Nlrc5 cooperates with the rfx transcription factor complex to induce mhc class I gene expression","volume":"188","author":"Meissner","year":"2012","journal-title":"J Immunol"},{"key":"B44","doi-asserted-by":"publisher","DOI":"10.1016\/j.celrep.2022.111384","article-title":"Circulating monocytes associated with anti-pd-1 resistance in human biliary cancer induce T cell paralysis","volume":"40","author":"Keenan","year":"2022","journal-title":"Cell Rep"},{"key":"B45","doi-asserted-by":"publisher","DOI":"10.1158\/2326-6066.CIR-19-0574","article-title":"Cd4(+) T-cell immunity in the peripheral blood correlates with response to anti-pd-1 therapy","volume":"8","author":"Kagamu","year":"2020","journal-title":"Cancer Immunol Res"},{"key":"B46","doi-asserted-by":"publisher","DOI":"10.1084\/jem.20200921","article-title":"Circulating clonally expanded T cells reflect functions of tumor-infiltrating T cells","volume":"218","author":"Lucca","year":"2021","journal-title":"J Exp Med"},{"key":"B47","doi-asserted-by":"publisher","first-page":"12991","DOI":"10.3390\/ijms232112991","article-title":"Changes in the immune cell repertoire for the treatment of Malignant melanoma","volume":"23","author":"Nakamura","year":"2022","journal-title":"Int J Mol Sci"},{"key":"B48","doi-asserted-by":"publisher","DOI":"10.1038\/s41591-021-01623-z","article-title":"T cell characteristics associated with toxicity to immune checkpoint blockade in patients with melanoma","volume":"28","author":"Lozano","year":"2022","journal-title":"Nat Med"},{"key":"B49","doi-asserted-by":"publisher","first-page":"19","DOI":"10.1038\/s41588-022-01268-9","article-title":"Multimodal single-cell and whole-genome sequencing of small, frozen clinical specimens","volume":"55","author":"Wang","year":"2023","journal-title":"Nat Genet"},{"key":"B50","doi-asserted-by":"publisher","DOI":"10.1038\/s41592-021-01201-8","article-title":"High-throughput and single-cell T cell receptor sequencing technologies","volume":"18","author":"Pai","year":"2021","journal-title":"Nat Methods"},{"key":"B51","doi-asserted-by":"publisher","first-page":"290","DOI":"10.1111\/j.1600-0749.2006.00322.x","article-title":"Metastatic potential of melanomas defined by specific gene expression profiles with no braf signature","volume":"19","author":"Hoek","year":"2006","journal-title":"Pigment Cell Res"},{"key":"B52","doi-asserted-by":"publisher","DOI":"10.1158\/0008-5472.CAN-07-2491","article-title":"In vivo switching of human melanoma cells between proliferative and invasive states","volume":"68","author":"Hoek","year":"2008","journal-title":"Cancer Res"},{"key":"B53","doi-asserted-by":"publisher","DOI":"10.1016\/j.semcancer.2020.01.009","article-title":"Tumor hypermetabolism confers resistance to immunotherapy","volume":"65","author":"Liu","year":"2020","journal-title":"Semin Cancer Biol"},{"key":"B54","doi-asserted-by":"publisher","DOI":"10.1038\/s41568-019-0154-4","article-title":"Phenotype plasticity as enabler of melanoma progression and therapy resistance","volume":"19","author":"Arozarena","year":"2019","journal-title":"Nat Rev Cancer"},{"key":"B55","doi-asserted-by":"publisher","first-page":"542","DOI":"10.1016\/j.cell.2017.01.010","article-title":"Genomic and transcriptomic features of response to anti-pd-1 therapy in metastatic melanoma","volume":"168","author":"Hugo","year":"2017","journal-title":"Cell"},{"key":"B56","doi-asserted-by":"publisher","DOI":"10.26508\/lsa.202101010","article-title":"Hierarchy of tgfbeta\/smad, hippo\/yap\/taz, and wnt\/beta-catenin signaling in melanoma phenotype switching","volume":"5","author":"Luond","year":"2022","journal-title":"Life Sci Alliance"},{"key":"B57","doi-asserted-by":"publisher","DOI":"10.1101\/gad.314617.118","article-title":"Roles of the immune system in cancer: from tumor initiation to metastatic progression","volume":"32","author":"Gonzalez","year":"2018","journal-title":"Genes Dev"},{"key":"B58","doi-asserted-by":"publisher","first-page":"1215","DOI":"10.1016\/j.immuni.2020.10.020","article-title":"Antagonistic inflammatory phenotypes dictate tumor fate and response to immune checkpoint blockade","volume":"53","author":"Bonavita","year":"2020","journal-title":"Immunity"},{"key":"B59","doi-asserted-by":"publisher","DOI":"10.1016\/j.cell.2015.08.015","article-title":"Cyclooxygenase-dependent tumor growth through evasion of immunity","volume":"162","author":"Zelenay","year":"2015","journal-title":"Cell"},{"key":"B60","doi-asserted-by":"publisher","first-page":"164","DOI":"10.1186\/s40001-022-00794-w","article-title":"Identification of rfx5 as prognostic biomarker and associated with immune infiltration in stomach adenocarcinoma","volume":"27","author":"Guo","year":"2022","journal-title":"Eur J Med Res"},{"key":"B61","doi-asserted-by":"publisher","DOI":"10.1136\/jitc-2020-000889","article-title":"Effect of cyclo-oxygenase inhibitor use during checkpoint blockade immunotherapy in patients with metastatic melanoma and non-small cell lung cancer","volume":"8","author":"Wang","year":"2020","journal-title":"J Immunother Cancer"},{"key":"B62","doi-asserted-by":"publisher","first-page":"38","DOI":"10.1016\/S2468-1253(21)00348-4","article-title":"Neoadjuvant pd-1 blockade with toripalimab, with or without celecoxib, in mismatch repair-deficient or microsatellite instability-high, locally advanced, colorectal cancer (Picc): A single-centre, parallel-group, non-comparative, randomised, phase 2 trial","volume":"7","author":"Hu","year":"2022","journal-title":"Lancet Gastroenterol Hepatol"},{"key":"B63","doi-asserted-by":"publisher","DOI":"10.1200\/JCO.2022.40.16_suppl.3511","article-title":"Neoadjuvant nivolumab, ipilimumab, and celecoxib in mmr-proficient and mmr-deficient colon cancers: final clinical analysis of the niche study","volume":"40","author":"Verschoor","year":"2022","journal-title":"J Clin Oncol"},{"key":"B64","doi-asserted-by":"publisher","DOI":"10.1200\/JCO.2023.41.16_suppl.9504","article-title":"Association of biomarkers (Bms) with efficacy of adjuvant nivolumab (Nivo) vs placebo (Pbo) in patients with resected stage iib\/C melanoma (Ca209-76k)","volume":"41","author":"Kirkwood","year":"2023","journal-title":"J Clin Oncol"},{"key":"B65","doi-asserted-by":"publisher","DOI":"10.1126\/science.aaf0683","article-title":"Rescue of exhausted cd8 T cells by pd-1-targeted therapies is cd28-dependent","volume":"355","author":"Kamphorst","year":"2017","journal-title":"Science"},{"key":"B66","doi-asserted-by":"publisher","first-page":"412","DOI":"10.1038\/s41392-021-00823-w","article-title":"T cell receptor (Tcr) signaling in health and disease","volume":"6","author":"Shah","year":"2021","journal-title":"Signal Transduct Target Ther"},{"key":"B67","doi-asserted-by":"publisher","DOI":"10.3389\/fimmu.2021.658611","article-title":"Naturally occurring genetic alterations in proximal tcr signaling and implications for cancer immunotherapy","volume":"12","author":"Kent","year":"2021","journal-title":"Front Immunol"},{"key":"B68","doi-asserted-by":"publisher","first-page":"2810","DOI":"10.3390\/ijms20112810","article-title":"The evolving role of cd8(+)Cd28(-) immunosenescent T cells in cancer immunology","volume":"20","author":"Huff","year":"2019","journal-title":"Int J Mol Sci"},{"key":"B69","doi-asserted-by":"publisher","DOI":"10.1016\/j.immuni.2016.04.020","article-title":"Cd28 costimulation: from mechanism to therapy","volume":"44","author":"Esensten","year":"2016","journal-title":"Immunity"},{"key":"B70","doi-asserted-by":"publisher","DOI":"10.1016\/j.immuni.2016.04.017","article-title":"Co-stimulatory and co-inhibitory pathways in autoimmunity","volume":"44","author":"Zhang","year":"2016","journal-title":"Immunity"},{"key":"B71","doi-asserted-by":"publisher","DOI":"10.1038\/s41590-022-01141-1","article-title":"A decade of checkpoint blockade immunotherapy in melanoma: understanding the molecular basis for immune sensitivity and resistance","volume":"23","author":"Huang","year":"2022","journal-title":"Nat Immunol"},{"key":"B72","doi-asserted-by":"publisher","DOI":"10.1146\/annurev-immunol-041015-055318","article-title":"Cd8 T cell exhaustion during chronic viral infection and cancer","volume":"37","author":"McLane","year":"2019","journal-title":"Annu Rev Immunol"},{"key":"B73","doi-asserted-by":"publisher","first-page":"2718","DOI":"10.3390\/cancers15102718","article-title":"Beyond ctla-4 and pd-1 inhibition: novel immune checkpoint molecules for melanoma treatment","volume":"15","author":"Ziogas","year":"2023","journal-title":"Cancers (Basel)"},{"key":"B74","doi-asserted-by":"publisher","first-page":"1342","DOI":"10.1038\/s41598-022-05474-7","article-title":"T cell subtype profiling measures exhaustion and predicts anti-pd-1 response","volume":"12","author":"Schillebeeckx","year":"2022","journal-title":"Sci Rep"},{"key":"B75","doi-asserted-by":"publisher","DOI":"10.3389\/fimmu.2020.00487","article-title":"The role of pd-1 in acute and chronic infection","volume":"11","author":"Jubel","year":"2020","journal-title":"Front Immunol"},{"key":"B76","doi-asserted-by":"publisher","first-page":"29","DOI":"10.1038\/ni.1679","article-title":"Coregulation of cd8+ T cell exhaustion by multiple inhibitory receptors during chronic viral infection","volume":"10","author":"Blackburn","year":"2009","journal-title":"Nat Immunol"},{"key":"B77","doi-asserted-by":"publisher","DOI":"10.1136\/jitc-2022-005052","article-title":"Multimodality analysis confers a prognostic benefit of a T-cell infiltrated tumor microenvironment and peripheral immune status in patients with melanoma","volume":"10","author":"Beasley","year":"2022","journal-title":"J\u00a0Immunother Cancer"},{"key":"B78","doi-asserted-by":"publisher","DOI":"10.1016\/j.celrep.2017.04.031","article-title":"Interferon receptor signaling pathways regulating pd-L1 and pd-L2 expression","volume":"19","author":"Garcia-Diaz","year":"2017","journal-title":"Cell Rep"},{"key":"B79","doi-asserted-by":"publisher","first-page":"1540","DOI":"10.1016\/j.cell.2016.11.022","article-title":"Tumor interferon signaling regulates a multigenic resistance program to immune checkpoint blockade","volume":"167","author":"Benci","year":"2016","journal-title":"Cell"},{"key":"B80","doi-asserted-by":"publisher","first-page":"200ra116","DOI":"10.1126\/scitranslmed.3006504","article-title":"Up-regulation of pd-L1, ido, and T(Regs) in the melanoma tumor microenvironment is driven by cd8(+) T cells","volume":"5","author":"Spranger","year":"2013","journal-title":"Sci Transl Med"},{"key":"B81","doi-asserted-by":"publisher","DOI":"10.1172\/JCI143296","article-title":"Interferons in cancer immunoediting: sculpting metastasis and immunotherapy response","volume":"131","author":"von Locquenghien","year":"2021","journal-title":"J Clin Invest"},{"key":"B82","doi-asserted-by":"publisher","first-page":"798","DOI":"10.1038\/nrc2734","article-title":"Stats in cancer inflammation and immunity: A leading role for stat3","volume":"9","author":"Yu","year":"2009","journal-title":"Nat Rev Cancer"},{"key":"B83","doi-asserted-by":"publisher","first-page":"42","DOI":"10.1016\/j.cyto.2017.03.018","article-title":"Stat3 in cancer: A double edged sword","volume":"98","author":"Avalle","year":"2017","journal-title":"Cytokine"},{"key":"B84","doi-asserted-by":"publisher","first-page":"7165","DOI":"10.1038\/s41467-024-51496-2","article-title":"Type I interferon signaling induces melanoma cell-intrinsic pd-1 and its inhibition antagonizes immune checkpoint blockade","volume":"15","author":"Holzgruber","year":"2024","journal-title":"Nat Commun"},{"key":"B85","doi-asserted-by":"publisher","DOI":"10.1038\/s41571-023-00760-3","article-title":"Personalizing neoadjuvant immune-checkpoint inhibition in patients with melanoma","volume":"20","author":"Lucas","year":"2023","journal-title":"Nat Rev Clin Oncol"},{"key":"B86","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMoa2402604","article-title":"Neoadjuvant nivolumab and ipilimumab in resectable stage iii melanoma","volume":"391","author":"Blank","year":"2024","journal-title":"N\u00a0Engl J Med"},{"key":"B87","doi-asserted-by":"publisher","DOI":"10.1016\/j.ejca.2024.115141","article-title":"Impact of personalized response-directed surgery and adjuvant therapy on survival after neoadjuvant immunotherapy in stage iii melanoma: comparison of 3-year data from prado and opacin-neo","volume":"214","author":"Reijers","year":"2025","journal-title":"Eur J Cancer"},{"key":"B88","doi-asserted-by":"publisher","first-page":"618","DOI":"10.1186\/s12964-024-01963-6","article-title":"Differentiation status determines the effects of ifngamma on the expression of pd-L1 and immunomodulatory genes in melanoma","volume":"22","author":"Saevarsson","year":"2024","journal-title":"Cell Commun Signal"},{"key":"B89","doi-asserted-by":"publisher","DOI":"10.1126\/scitranslmed.aaz6314","article-title":"Reprogramming lipid metabolism prevents effector T cell senescence and enhances tumor immunotherapy","volume":"13","author":"Liu","year":"2021","journal-title":"Sci Transl Med"}],"container-title":["Frontiers in Immunology"],"original-title":[],"link":[{"URL":"https:\/\/www.frontiersin.org\/articles\/10.3389\/fimmu.2025.1529707\/full","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,3,28]],"date-time":"2025-03-28T09:38:50Z","timestamp":1743154730000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.frontiersin.org\/articles\/10.3389\/fimmu.2025.1529707\/full"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2025,3,28]]},"references-count":89,"alternative-id":["10.3389\/fimmu.2025.1529707"],"URL":"https:\/\/doi.org\/10.3389\/fimmu.2025.1529707","relation":{},"ISSN":["1664-3224"],"issn-type":[{"value":"1664-3224","type":"electronic"}],"subject":[],"published":{"date-parts":[[2025,3,28]]},"article-number":"1529707"}}